The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 23, 2021
Filed:
Dec. 14, 2016
Applicants:
X4 Pharmaceuticals, Inc., Cambridge, MA (US);
Genzyme Corp., Cambridge, MA (US);
Inventors:
Paula Marie Ragan, Belmont, MA (US);
Robert D. Arbeit, West Newton, MA (US);
Kieran James Crowley, Highland Park, NJ (US);
Assignees:
X4 PHARMACEUTICALS, INC., Cambridge, MA (US);
GENZYME CORP., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4709 (2006.01); A61K 9/48 (2006.01); A61K 9/14 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4709 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01); A61K 9/14 (2013.01);
Abstract
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.